Ref. | n | Year | Study design | Level of evidence | Comparator | Dose | End-points |
---|---|---|---|---|---|---|---|
[60]a | 45 | 2002 | Prospective, blinded, randomized controlled trial | II | Amrinone/placebo | 50 μg/kg then 0.5 μg/kg per min | Haemodynamic parameters |
[75] | 20 | 2002 | Observational study | III | - | 20 μg/kg | Haemodynamic parameters |
[76] | 20 | 2002 | Observational study | III | - | 50 μg/kg | Middle cerebral artery flow |
[2]b,c | 120 | 2001 | Multicentre, prospective, randomized trial | I | Dobutamine | 50 μg/kg then 0.5 μg/kg per min | Haemodynamic parameters |
[77]b | 20 | 2001 | Prospective, blinded, randomized controlled trial | II | Control | 0.5 μg/kg per min | Haemodynamic parameters |
[78] | 20 | 2001 | Prospective, randomized, placebo-controlled trial | II | Placebo | 0.25 μg/kg per min | pHi, inflammatory markers |
[64]b | 29 | 2000 | Prospective, randomized trial | II | Amrinone, olprinone | 50 μg/kg | pHi, hepatic blood flow, oxygenation |
[79]c | 45 | 2000 | Prospective, randomized trial | II | NO | 50 μg/kg then 0.5 μg/kg per min | Haemodynamic parameters; RVEF |
[9] | 20 | 2000 | Prospective, randomized trial | II | Epinephrine | 50 μg/kg | Haemodynamic parameters |
[80] | 48 | 2000 | Prospective, blinded, randomized, placebo-controlled trial | II | Placebo | 20 μg/kg then 0.2 μg/kg per min | Haemodynamic parameters |
[13]b | 20 | 2000 | Prospective, randomized trial | II | Epinephrine | 50 μg/kg | IMA flow |
[81] | 24 | 1999 | Prospective, randomized controlled trial | II | Control | 50 μg/kg | Inflammatory markers |
[27]b | 24 | 1999 | Prospective, blinded, randomized, placebo-controlled trial | II | Dopamine, placebo | 50 μg/kg then 0.375 μg/kg per min | pHi, SHVO2, endotoxin levels |
[82]b | 22 | 1999 | Prospective, randomized, placebo-controlled trial | II | Placebo | 30 μg/kg then 0.5 μg/kg per min | Haemodynamic parameters |
[83]a,c | 21 | 1998 | Prospective, blinded, randomized, placebo-controlled trial | II | Placebo | 50 μg/kg | Haemodynamic parameters |
[62]b | 44 | 1998 | Prospective, multicentre, randomized trial | II | Amrinone | Two boluses of 25 μg/kg | Haemodynamic parameters |
[84]b | 37 | 1997 | Prospective, randomized controlled trial | II | Control | 50/75 μg/kg then 0.5/0.75 μg/kg per min | Haemodynamic parameters |
[85]a,c | 32 | 1997 | Prospective, blinded, randomized, placebo-controlled trial | II | Placebo | 50 μg/kg then 0.5 μg/kg per min | Haemodynamic parameters |
[86]b | 24 | 1996 | Observational study | III | - | 25–75 μg/kg then 0.5 μg/kg per min for 1 hour | Haemodynamic parameters |
[87]b | 29 | 1995 | Observational study | III | - | 25–75 μg/kg | Haemodynamic parameters |
[88]a | 20 | 1995 | Prospective, blinded, randomized trial | II | - | 20 and 40 μg/kg then 0.5 μg/kg per min | Haemodynamic parameters |
[89]b | 25 | 1994 | Observational study | III | - | 25, 50, 75 μg/kg or 0.5 μg/kg per min | Plasma concentration |
[90]b,c | 12 | 1994 | Observational study | III | - | 50 μg/kg then 0.5 μg/kg per min | Plasma concentration |
[91,92]b,c | 99 | 1992 | Observational study | III | - | 50 μg/kg then 0.375–0.75 μg/kg per min | Haemodynamic parameters |
[93]b,c | 24 | 1992 | Observational study | III | - | 50 μg/kg then 0.375–0.75 μg/kg per min | Haemodynamic parameters |
[94]b,c | 35 | 1991 | Observational study | III | - | 50 μg/kg then 0.375–0.75 μg/kg per min | Haemodynamic parameters |